



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/032,239	12/21/2001	Michael Weickert	0067.00	6675
21968 7590 01/16/2007 NEKTAR THERAPEUTICS 150 INDUSTRIAL ROAD SAN CARLOS, CA 94070			EXAMINER WANG, SHENGJUN	
			ART UNIT	PAPER NUMBER
			1617	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
2 MONTHS		01/16/2007	PAPER	

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.



UNITED STATES PATENT AND TRADEMARK OFFICE

---

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**RECEIVED**

JAN 16 2007

**TECH CENTER 1600/2900**

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 10/032,239  
Filing Date: December 21, 2001  
Appellant(s): WEICKERT ET AL.

---

Michael J. Mazza  
For Appellant

**EXAMINER'S ANSWER**

This is in response to the appeal brief filed October 6, 2006 appealing from the Office action mailed July 14, 2004.

**(1) Real Party in Interest**

A statement identifying by name the real party in interest is contained in the brief.

**(2) Related Appeals and Interferences**

The examiner is not aware of any related appeals, interferences, or judicial proceedings which will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

**(3) Status of Claims**

The statement of the status of claims contained in the brief is correct.

**(4) Status of Amendments After Final**

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

**(5) Summary of Claimed Subject Matter**

The summary of claimed subject matter contained in the brief is correct.

**(6) Grounds of Rejection to be Reviewed on Appeal**

The appellant's statement of the grounds of rejection to be reviewed on appeal is correct.

**(7) Claims Appendix**

The copy of the appealed claims contained in the Appendix to the brief is correct.

**(8) Evidence Relied Upon**

Art Unit: 1617

The following is a listing of the evidence (e.g., patents, publications, Official Notice, and admitted prior art) relied upon in the rejection of claims under appeal.

US Patent 5,965,156	Proffitt et al.	October 12, 1999
US Patent 6,077,543	Gordon et al.	June 20, 2000
US Patent 4,016,254	Seager	April 5, 1977
WO 97/03649	Staniforth	February 6, 1997

**(9) Grounds of Rejection*****Rejections 35 U.S.C. 103***

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 40, and 42-59 are rejected under 35 U.S.C. 103(a) as being unpatentable over Proffitt et al. (US. 5,965,156), in view of Staniforth (WO 97/03649, IDS) and Gordon et al. (US 6,077,543, IDS).
3. Proffitt et al. teaches an amphotericin liposome powder with diameters less than 2  $\mu\text{m}$ , which may be obtained through a spray drying of an acidified solution of amphotericin. The powders characterized as stable and less toxic. See, particularly, column 4, line 55 to column 7, line 35, and the claims. Further, it is well known that amphotericin B is useful for treating fungal infections. See, particularly, column 1, lines 30-45.

Art Unit: 1617

4. Proffitt et al. does not teach expressly a powder contains more than 30% by weight of amphotericin, which is for inhalation.

5. However, Staniforth teaches that powder composition for inhalation generally comprising high concentration of active ingredient, (e.g., 60% or higher by weight). See, the abstract. The optimal particle size for lung inhalation administration is 0.1  $\mu$ m to 5 $\mu$ m and leucin is added as anti-adherent material. See, particularly, the abstract. Gordon et al. teaches that hydrophobic drugs for lung delivery, such as amphotericin B are known to be made into particles less than 5  $\mu$ m in size. See, particularly, column 1, lines 52-67, column 5, line 20 to column 6, lines 62.

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to make a stable amphotericin powder composition for inhalation administration by drying a acidified solution of amphotericin according to Proffitt's method (without adding the other ingredients required for the liposome composition).

A person of ordinary skill in the art would have been motivated to make a stable amphotericin powder composition for inhalation administration by drying a acidified solution of amphotericin according to Proffitt's method (without adding the other ingredients required for the liposome composition) because Proffitt's method is known to provide stable amphotericin composition. Further, making a powder composition suitable for inhalation (i.e., with certain size of the particle) administration, or controlling degradation of the active ingredient during the process of making, is a matter of optimization of a result effective parameter, which is considered within the skill of the artisan, particularly in view of the fact that method of making such powders is well-known in the art (see Staniforth et al. and Gordon et al). See, In re Boesch

Art Unit: 1617

and Slaney (CCPA) 204 USPQ 215. Further, it would have been obvious to employ a known antifungal agent for treating fungal infection patient.

6. Claims 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Proffitt et al. (US 5,965,156), in view of Staniforth (WO 97/03649, IDS) and Gorden et al. (US 6,077,543, IDS) for reasons set forth above, and in further view of Seager et al.

7. Proffitt et al., Staniforth and Gorden et al. taken together do not teach expressly the employment of aqueous suspension, wet milling and spray drying to make the powder.

8. However, it would have been obvious to one of ordinary skill in the art, at the time the claimed invention was made to employ wet milling-spray drying technique for making a powder because such technique is well known in the art for making fine particles. See, e.g., column 8, line 66 to column 9, line 10.

#### **(10) Response to Argument**

9. In response to appellants' arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). One of ordinary skill in the art, possessing the knowledge disclosed in the cited references, would have seen the claimed invention obvious. Particularly, knowing the technique of making a stable polyene particles as disclosed by Proffitt, and the employment of amphotericin B for lung delivery, one of ordinary skill in the art would have combined the known knowledge of making polyene aerosol to arrive at the claimed invention.

In response to appellants' argument that there is no suggestion to combine the references, the examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, the teaching, suggestion and motivation are found in the cited references and in the knowledge generally available to one of ordinary skill in the art.

Appellants further argue that the dry powder disclosed by Proffitt et al. is not suitable for lung delivery. The examiner contends that a prima facie case that the dry powder of Proffitt is not suitable for lung delivery has not been established on the record.

10. Further, it is noted that Proffitt teaches dried monohydrated stable powders. See, particularly, column 5, lines 26-43, and examples 1 in column 8. Therefore, Proffitt's method is suitable for make aerosol dried powder.

Furthermore, as to process recited in the claims, it is further noted that "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." *In re Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (see also MPEM 2113).

Art Unit: 1617


**(11) Related Proceeding(s) Appendix**

No decision rendered by a court or the Board is identified by the examiner in the Related Appeals and Interferences section of this examiner's answer.

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,

Shengjun Wang


  
SHENGJUN WANG  
PRIMARY EXAMINER

Conferees:

Sreeni Padmanabhan

San-ming Hui

  
SAN-MING HUI  
PRIMARY EXAMINER

  
SREENI PADMANABHAN  
SUPERVISORY PATENT EXAMINER